Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01076842 · ClinicalTrials.gov registry record · Phase 4
Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment
A Phase 4 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
NCT01076842 is a Phase 4 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 75 participants.
The verdict
NCT01076842, a Phase 4 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of two different kinds of diabetes medications, insulin detemir (Levemir) and exenatide (Byetta), in improving blood sugar levels with little or no weight gain in patients with type 2 diabetes who are not well controlled on two or more oral (by mouth) diabetes medications. Both medications are given by injection with a very small needle just below the surface of your skin (called subcutaneous injection). The medication that you inject will be in addition to your oral medications.
Interventions
- DRUG Insulin-Levemir
- DRUG Exenatide-Bayetta
- DRUG Insulin-Levemir and Exenatide-Bayetta
- DEVICE SenseWear Pro3® armband
- DEVICE DexCom CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01076842
The ClinicalTrials.gov registry entry for NCT01076842 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Insulin-Levemir is the first listed.
NCT01076842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01076842 about?
NCT01076842 is a clinical study titled "Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment". The purpose of this study is to compare the effectiveness of two different kinds of diabetes medications, insulin detemir (Levemir) and exenatide (Byetta), in improving blood sugar levels with little or no weight gain in patients with type 2 diabetes who are not well controlled on two or more oral (...
What is the current status of trial NCT01076842?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2008-04. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01076842?
The interventions under investigation include: Insulin-Levemir (DRUG), Exenatide-Bayetta (DRUG), Insulin-Levemir and Exenatide-Bayetta (DRUG), SenseWear Pro3® armband (DEVICE), DexCom CGM (DEVICE).
Who is sponsoring clinical trial NCT01076842?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.